1-10 of 10
Anthony M. Joshua
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Neil E. Fleshner, Rashid K. Sayyid, Aaron R. Hansen, Joseph L.K. Chin, Ricardo Fernandes, Eric Winquist, Theodorus van der Kwast, Joan Sweet, Katherine Lajkosz, Miran Kenk, Karen Hersey, Rosette Veloso, Doron Berlin, Jaime O. Herrera-Caceres, Srikala Sridhar, Madeleine Moussa, Antonio Finelli, Robert J. Hamilton, Girish S. Kulkarni, Alexandre R. Zlotta, Anthony M. Joshua
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3867–3874.
https://doi.org/10.1158/1078-0432.CCR-23-0731
Published: 02 October 2023
View articletitled, Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Open the PDF for Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial in another window
Includes: Supplementary data
Journal Articles

A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud, Anthony M. Joshua, José Luis Pérez-Gracia, Casilda Llácer Pérez, Sang Joon Shin, Bruno Fang, Minal Barve, Marco Maruzzo, Sergio Bracarda, Miso Kim, Yannick Kerloeguen, Jorge Daniel Gallo, Sophia L. Maund, Adam Harris, Kuan-Chieh Huang, Victor Poon, Dhruvitkumar S. Sutaria, Howard Gurney
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3292–3300.
https://doi.org/10.1158/1078-0432.CCR-22-2585
Published: 01 September 2023
View articletitled, A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
Open the PDF for A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Yi Liang, Sujeeve Jeganathan, Stefano Marastoni, Adam Sharp, Ines Figueiredo, Richard Marcellus, Amanda Mawson, Zvi Shalev, Aleksandra Pesic, Joan Sweet, Haiyang Guo, David Uehling, Bora Gurel, Antje Neeb, Housheng Hansen He, Bruce Montgomery, Marianne Koritzinsky, Samantha Oakes, Johann S. de Bono, Martin Gleave, Amina Zoubeidi, Bradly G. Wouters, Anthony M. Joshua
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2340–2351.
https://doi.org/10.1158/1078-0432.CCR-20-3260
Published: 15 April 2021
View articletitled, Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Open the PDF for Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies in another window
Includes: Supplementary data
Journal Articles

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 6098.
https://doi.org/10.1158/1078-0432.CCR-18-3340
Published: 03 December 2018
View articletitled, Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Journal Articles

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (20): 4960–4967.
https://doi.org/10.1158/1078-0432.CCR-17-2386
Published: 15 October 2018
View articletitled, Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients

Juozas Gordevičius, Algimantas Kriščiūnas, Daniel E. Groot, Steven M. Yip, Miki Susic, Andrew Kwan, Rafal Kustra, Anthony M. Joshua, Kim N. Chi, Art Petronis, Gabriel Oh
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3317–3324.
https://doi.org/10.1158/1078-0432.CCR-18-0101
Published: 15 July 2018
View articletitled, Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Open the PDF for Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Enzalutamide Prior to Prostatectomy

Bruce Montgomery, Maria S. Tretiakova, Anthony M. Joshua, Martin E. Gleave, Neil Fleshner, Glenn J. Bubley, Elahe A. Mostaghel, Kim N. Chi, Daniel W. Lin, Martin Sanda, William Novotny, Kenneth Wu, Philip W. Kantoff, Brett T. Marck, Stephen Plymate, Steven P. Balk, Peter S. Nelson, Alvin M. Matsumoto, Rosina T. Lis, Adam Kibel, Gabriel P. Haas, Andrew Krivoshik, Alison Hannah, Mary-Ellen Taplin
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (9): 2169–2176.
https://doi.org/10.1158/1078-0432.CCR-16-1357
Published: 30 April 2017
View articletitled, Neoadjuvant Enzalutamide Prior to Prostatectomy
Open the PDF for Neoadjuvant Enzalutamide Prior to Prostatectomy in another window
Includes: Supplementary data
Journal Articles

Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Gerhardt Attard, Johann S. de Bono, Christopher J. Logothetis, Karim Fizazi, Som D. Mukherjee, Anthony M. Joshua, Dirk Schrijvers, Alfons J.M. van den Eertwegh, Weimin Li, Arturo Molina, Thomas W. Griffin, Thian Kheoh, Deborah S. Ricci, Kathy Zelinsky, Dana E. Rathkopf, Howard I. Scher, Charles J. Ryan
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1621–1627.
https://doi.org/10.1158/1078-0432.CCR-14-1961
Published: 31 March 2015
View articletitled, Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Open the PDF for Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate in another window
Includes: Supplementary data
Journal Articles

TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Alan Dal Pra, Emilie Lalonde, Jenna Sykes, Fiona Warde, Adrian Ishkanian, Alice Meng, Chad Maloff, John Srigley, Anthony M. Joshua, Gyorgy Petrovics, Theodorus van der Kwast, Andrew Evans, Michael Milosevic, Fred Saad, Colin Collins, Jeremy Squire, Wan Lam, Tarek A. Bismar, Paul C. Boutros, Robert G. Bristow
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (18): 5202–5209.
https://doi.org/10.1158/1078-0432.CCR-13-1049
Published: 16 September 2013
View articletitled, TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Open the PDF for TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair in another window
Includes: Supplementary data
Journal Articles

PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy

Michael Fraser, Helen Zhao, Kaisa R. Luoto, Cecilia Lundin, Carla Coackley, Norman Chan, Anthony M. Joshua, Tarek A. Bismar, Andrew Evans, Thomas Helleday, Robert G. Bristow
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1015–1027.
https://doi.org/10.1158/1078-0432.CCR-11-2189
Published: 14 February 2012
View articletitled, PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Open the PDF for PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy in another window
Includes: Supplementary data